{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:54:24Z","timestamp":1790009664712,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platinum-resistant ovarian cancer (PROC) has a poor prognosis and limited treatments. Relacorilant plus nab-paclitaxel (RnP) shows clinical efficacy in Phase III trials, but its cost-effectiveness has not yet been evaluated. This study evaluated RnP versus nab-paclitaxel (nP) for PROC from the U.S. payers\u2019 perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model (1-month cycle, 5-year time horizon) was utilized to assess the cost-effectiveness of the RnP regimen for PROC, and appropriate parametric functions were applied to fit survival curves and extrapolate 5 years of treatment. Critical clinical data were derived from the ROSELLA trial. Costs and utility values were obtained from U.S. public websites and published literature. The primary outcomes were total cost, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER), which was benchmarked against a willingness-to-pay (WTP) threshold of $150,000\/QALY. A comprehensive appraisal of model robustness was conducted, encompassing both one-way sensitivity analysis and probabilistic sensitivity analyses (PSA), in addition to scenario analyses to probe the conditions for the regimen\u2019s economic feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the nP regimen, the RnP regimen incurred an additional treatment cost of $43,161 but gained an extra 0.27 QALYs in health benefits. Ultimately, the ICER was calculated to be $161,753\/QALY, which exceeded the WTP threshold of $150,000\/QALY. One-way sensitivity analysis demonstrated that the price of relacorilant had the greatest influence on results, with the PSA showing a 38.9% probability of the RnP regimen being cost-effective. The probabilities that the RnP regimen was cost-effective for PROC were 2.3%, 38.9%, and 82.4% at WTP thresholds of $100,000, $150,000, and $200,000\/QALY, respectively. Scenario analyses identified a definitive price threshold for relacorilant ($2.262\/mg), representing a 7.8% reduction from the current estimated cost, at which the RnP regimen achieves cost-effectiveness. Subgroup analyses found that the RnP regimen was associated with a relative cost-effective outcome in several subgroups: those aged\u2009&gt;\u200965 years, patients with a primary platinum-free treatment interval\u2009\u2264\u20096 months, and patients with a taxane-free interval\u2009\u2264\u20096 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the U.S. payers\u2019 perspective, the RnP regimen is not cost-effective compared with the nP regimen for patients with PROC. Setting relacorilant\u2019s price at $2.262\/mg could render the RnP regimen cost-effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-026-02109-7","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:06:13Z","timestamp":1776909973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Shubin","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2184-7591","authenticated-orcid":false,"given":"Honglin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2109_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"2109_CR2","unstructured":"Institute. national cancer seer cancer stat facts: ovarian cancer. Accessed 10.18. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"2109_CR3","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology (NCCN guidelines\u00ae): ovarian cancer, version 3.2025. 2025. Accessed 10.18."},{"key":"2109_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the aurelia open-label randomized phase iii trial. J Clin Oncol. 2014;32:1302\u20138.","journal-title":"J Clin Oncol"},{"key":"2109_CR5","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase iii study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312\u201322.","journal-title":"J Clin Oncol"},{"key":"2109_CR6","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage iii or iv ovarian cancer: placebo-controlled randomized phase iii trial (imagyn050\/gog 3015\/engot-ov39). J Clin Oncol. 2021;39:1842\u201355.","journal-title":"J Clin Oncol"},{"key":"2109_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","volume":"405","author":"AB Olawaiye","year":"2025","unstructured":"Olawaiye AB, Gladieff L, O\u2019Malley DM, et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (rosella): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025;405:2205\u201316.","journal-title":"Lancet"},{"key":"2109_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/14737140.2024.2362178","volume":"24","author":"E Giudice","year":"2024","unstructured":"Giudice E, Salutari V, Sassu CM, et al. Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. Expert Rev Anticancer Ther. 2024;24:649\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2109_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eprac.2023.09.011","volume":"30","author":"DM Donegan","year":"2024","unstructured":"Donegan DM, Pivonello R, Stigliano A, et al. Relacorilant, a selective glucocorticoid receptor modulator in development for the treatment of patients with cushing syndrome, does not cause prolongation of the cardiac qt interval. Endocr Pract. 2024;30:11\u20138.","journal-title":"Endocr Pract"},{"key":"2109_CR10","doi-asserted-by":"publisher","first-page":"110312","DOI":"10.1016\/j.intimp.2023.110312","volume":"120","author":"AE Greenstein","year":"2023","unstructured":"Greenstein AE, Hunt HJ. The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol. Int Immunopharmacol. 2023;120:110312.","journal-title":"Int Immunopharmacol"},{"key":"2109_CR11","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-21-4363","volume":"28","author":"PN Munster","year":"2022","unstructured":"Munster PN, Greenstein AE, Fleming GF, et al. Overcoming taxane resistance: preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clin Cancer Res. 2022;28:3214\u201324.","journal-title":"Clin Cancer Res"},{"key":"2109_CR12","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.3802\/jgo.2025.36.e4","volume":"36","author":"M Taya","year":"2025","unstructured":"Taya M, Hou X, Veneris JT, et al. Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer pdx models. J Gynecol Oncol. 2025;36:e4.","journal-title":"J Gynecol Oncol"},{"key":"2109_CR13","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Nadauld LD, Hoover S. The high costs of anticancer therapies in the usa: challenges, opportunities and progress. Nature reviews. Clinical oncology. 2024;21(12):888\u2009\u2013\u200999. https:\/\/doi.org\/10.1038\/s41571-024-00948-1","DOI":"10.1038\/s41571-024-00948-1"},{"key":"2109_CR14","first-page":"e112","volume":"Oncology","author":"L Schnipper","year":"2014","unstructured":"Schnipper L, Neumann P, Bach PB. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet. 2014;Oncology:e112\u20138.","journal-title":"Lancet"},{"key":"2109_CR15","unstructured":"Saudi food and. drug authority. Economic evaluation studies guidelines. Riyadh: sfda. 2024."},{"key":"2109_CR16","doi-asserted-by":"crossref","unstructured":"Johnston BJ, Miller KL, Nguyen AH et al. A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer. Translational cancer Res. 2025:3161\u201374.","DOI":"10.21037\/tcr-2025-641"},{"key":"2109_CR17","doi-asserted-by":"publisher","unstructured":"Brown AN, Miller DS, Ledermann JA. Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease. Front Oncol. 2026; 16:1765220. https:\/\/doi.org\/10.3389\/fonc.2026.1765220","DOI":"10.3389\/fonc.2026.1765220"},{"key":"2109_CR18","doi-asserted-by":"publisher","unstructured":"Chen L, Zhang Y, Wang H, Li J. Related clinical factors of platinum-based chemotherapy resistance in patients with epithelial ovarian cancer. Gynecol Obstet Invest. 2024; 89(6):469\u201377. https:\/\/doi.org\/10.1159\/000539295","DOI":"10.1159\/000539295"},{"key":"2109_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00019053-199711020-00005","volume":"11","author":"JE Siegel","year":"1997","unstructured":"Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. PharmacoEconomics. 1997;11:159\u201368.","journal-title":"PharmacoEconomics"},{"key":"2109_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.lungcan.2019.10.017","volume":"138","author":"L She","year":"2019","unstructured":"She L, Hu H, Liao M, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with pd-l1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88\u201394.","journal-title":"Lung Cancer"},{"key":"2109_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1177\/0272989X19875950","volume":"39","author":"A Vickers","year":"2019","unstructured":"Vickers A. An evaluation of survival curve extrapolation techniques using long-term observational cancer data. Med Decis Mak. 2019;39:926\u201338.","journal-title":"Med Decis Mak"},{"key":"2109_CR22","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.3802\/jgo.2024.35.e71","volume":"35","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Lin Y, Liu K, Zhu H. Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J Gynecol Oncol. 2024;35:e71.","journal-title":"J Gynecol Oncol"},{"key":"2109_CR23","unstructured":"Centers for disease control and prevention. Body measurements. 2025. Accessed February 1. https:\/\/www.cdc.gov\/nchs\/fastats\/body-measurements.htm"},{"key":"2109_CR24","doi-asserted-by":"publisher","first-page":"e2512455","DOI":"10.1001\/jamanetworkopen.2025.12455","volume":"8","author":"M Zhao","year":"2025","unstructured":"Zhao M, Shao T, Yin Y, Fang H, Shao H, Tang W. Adverse event costs and cost-effectiveness analyses of anticancer drugs: a systematic review. JAMA Netw Open. 2025;8:e2512455.","journal-title":"JAMA Netw Open"},{"key":"2109_CR25","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.22.02624","volume":"41","author":"N Colombo","year":"2023","unstructured":"Colombo N, Van Gorp T, Matulonis UA, et al. Relacorilant\u2009+\u2009nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase ii study. J Clin Oncol. 2023;41:4779\u201389.","journal-title":"J Clin Oncol"},{"key":"2109_CR26","doi-asserted-by":"publisher","unstructured":"Nanda R, Stringer-Reasor EM, Saha P, et al. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus. 2016;5:947. https:\/\/doi.org\/10.1186\/s40064-016-2457-1.","DOI":"10.1186\/s40064-016-2457-1"},{"key":"2109_CR27","unstructured":"Drug.com. Mifepristone: prices, coupons, and savings information. 2026. Accessed February 1. https:\/\/www.drug.com\/price-guide\/mifepristone"},{"key":"2109_CR28","unstructured":"Drug.com. Abraxane price,cupons cards & patient assistance. 2026. Accessed 1.29. https:\/\/www.drugs.com\/price-guide\/abraxane"},{"key":"2109_CR29","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/hed.27452","volume":"45","author":"J Han","year":"2023","unstructured":"Han J, Zeng N, Tian K, et al. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated network meta-analysis and cost-effectiveness analysis. Head Neck. 2023;45:2246\u201358.","journal-title":"Head Neck"},{"key":"2109_CR30","doi-asserted-by":"publisher","first-page":"1527614","DOI":"10.3389\/fphar.2025.1527614","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Li Y, Liu Y, Li H, Wang H. Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with egfr mutations. Front Pharmacol. 2025;16:1527614.","journal-title":"Front Pharmacol"},{"key":"2109_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14622416.2024.2344438","volume":"25","author":"S Lai","year":"2024","unstructured":"Lai S, Luo S, Huang Q, et al. The cost-effectiveness of zolbetuximab in cldn18.2-positive gastric or gastroesophageal junction adenocarcinoma. Pharmacogenomics. 2024;25:249\u201357.","journal-title":"Pharmacogenomics"},{"key":"2109_CR32","unstructured":"CMS. 2026 physician fee schedule final rule. 2025. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched"},{"key":"2109_CR33","doi-asserted-by":"publisher","first-page":"851522","DOI":"10.3389\/fonc.2022.851522","volume":"12","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Zhang Q. Cost-effectiveness of nivolumab plus chemotherapy vs. Chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophagel adenocarcinoma in china. Front Oncol. 2022;12:851522.","journal-title":"Front Oncol"},{"key":"2109_CR34","unstructured":"2024 U.S. Dollar values using the u.s. Consumer price index (CPI). Accessed 9.20. https:\/\/www.officialdata.org\/us\/inflation\/2024"},{"key":"2109_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.","journal-title":"Health Qual Life Outcomes"},{"key":"2109_CR36","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159\u201370.","journal-title":"N Engl J Med"},{"key":"2109_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9:851\u20139.","journal-title":"JAMA Oncol"},{"key":"2109_CR38","doi-asserted-by":"publisher","first-page":"e2400313","DOI":"10.1200\/GO-24-00313","volume":"11","author":"B Hutchinson","year":"2025","unstructured":"Hutchinson B, Euripides M, Reid F, et al. Socioeconomic burden of ovarian cancer in 11 countries. JCO Glob Oncol. 2025;11:e2400313.","journal-title":"JCO Glob Oncol"},{"key":"2109_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/13696998.2020.1815025","volume":"23","author":"NS Alkhatib","year":"2020","unstructured":"Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting: delta1: cost effectiveness analysis and cost-utility analysis-based pricing. J Med Econ. 2020;23:1215\u201322.","journal-title":"J Med Econ"},{"key":"2109_CR40","doi-asserted-by":"publisher","unstructured":"Zhou Y, Tong F, Jin B et al. Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study. J gynecologic Oncol. 2025;36(4):e63. https:\/\/doi.org\/10.3802\/jgo.2025.36.e63.","DOI":"10.3802\/jgo.2025.36.e63"},{"key":"2109_CR41","doi-asserted-by":"publisher","unstructured":"Chen S, Liu Y, Wu S et al. Cost-effectiveness of maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. J Natl Compr Cancer Network: JNCCN. 2020;18(11):1528\u201336. https:\/\/doi.org\/10.6004\/jnccn-2020-1018.","DOI":"10.6004\/jnccn-2020-1018"},{"key":"2109_CR42","doi-asserted-by":"publisher","unstructured":"Chen L, Zhang Y, Wang H et al. Cost-effectiveness of benmelstobart-anlotinib-chemotherapy in extensive-stage small-cell lung cancer: a comparative analysis across united states and chinese healthcare systems. Int J Clin Pharm. 2025;47(3):1493\u2013509. https:\/\/doi.org\/10.1007\/s11096-025-01867-3.","DOI":"10.1007\/s11096-025-01867-3"},{"key":"2109_CR43","doi-asserted-by":"crossref","unstructured":"Gerber DE, Patel NM, Chou S et al. Cost-effectiveness of cemiplimab versus standard of care in the united states for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression\u2009\u2265\u200950. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2022;20(2):203\u201314. https:\/\/jnccn.org\/view\/journals\/jnccn\/2022\/02021-0187","DOI":"10.1016\/j.jval.2021.08.009"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02109-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:35:43Z","timestamp":1781649343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02109-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2109"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02109-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.This study uses only publicly available phase III clinical trial data and involves no human participation or original data collection, and is therefore exempt from ethical approval in accordance with relevant norms.The study strictly adheres to the 2024 Declaration of Helsinki: all data are sourced from ethically approved public trials, participant privacy is protected, and no identifiable information is used.As the original trials obtained participant consent in compliance with ethical guidelines, no additional informed consent is required for this secondary data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}